TL;DR
This paper uses bibliometric analysis to map the research landscape of pulmonary fibrosis complicated by lung cancer from 2004-2024. It reveals a growing research interest, identifies key countries, institutions, and authors, and highlights emerging trends and future research directions, particularly in targeted therapies and biomarkers.
What Problem Does This Paper Address?
Pulmonary fibrosis (PF) and lung cancer (LC) are significant global health burdens, and their comorbidity presents a complex clinical challenge. While research on each disease individually is extensive, a comprehensive understanding of the research trends, key players, and future directions specifically for their co-occurrence has been lacking. This paper aims to fill this gap by providing a data-driven overview of the scientific literature on this comorbidity, offering insights for researchers and clinicians.
Methods
The study employs a bibliometric analysis approach, utilizing data from the Web of Science Core Collection (WoSCC) database. The researchers retrieved articles and reviews published between 2004 and April 2024. They then used a suite of tools for analysis and visualization:
- CiteSpace: For identifying and eliminating duplicate publications, analyzing keyword clusters, and visualizing research frontiers and citation bursts.
- VOSviewer: For constructing and visualizing bibliometric networks, including author, journal, and country collaboration maps, as well as keyword co-occurrence networks.
- R (with the bibliometrix package) and Biblioshiny: For statistical calculations, data analysis, and generating various bibliometric maps and tables.
The analysis focused on publication trends, country and institutional contributions, influential authors, co-cited references, and keyword evolution to map the research landscape.
Datasets
The primary dataset for this study consists of all English-language Articles and Reviews related to "pulmonary fibrosis and lung cancer" retrieved from the Web of Science Core Collection (WoSCC) database. A total of 2,234 documents (1,804 articles and 430 reviews) were included in the final analysis after screening and deduplication. No new benchmarks were introduced; the study relies on existing literature indexed in WoSCC.
Key Insights and Ideas
- Growing Research Interest: The field is experiencing a continuous upward trend in publications, indicating increasing scientific attention to the comorbidity of pulmonary fibrosis and lung cancer.
- Geographic Contributions: The United States, Japan, and China are the leading countries in terms of publication volume, suggesting significant research efforts in these regions.
- Key Research Hubs: Specific institutions, such as the University of Michigan and Mayo Clinic, are prominent contributors, highlighting their role in advancing research in this area.
- Emerging Therapeutic Frontiers: The analysis points towards "nintedanib," "pirfenidone," and "immunotherapy" as key emerging research topics, signaling a shift towards targeted therapies and novel treatment strategies.
- Clinical Focus: A significant portion of the research is clinically oriented, focusing on diagnosis, prognosis, survival, and risk assessment, underscoring the translational aspect of this research.
- Biomarker Potential: The identification of biomarkers for early detection and prognosis is highlighted as a crucial area for future research, bridging the gap between basic science and clinical application.
- Tumor Microenvironment: The interplay between the fibrotic microenvironment and cancer progression is emerging as a significant research theme, suggesting a deeper understanding of the complex interactions between PF and LC.
Key Results
- A total of 2,234 publications (Articles and Reviews) were analyzed, published between 2004 and 2024.
- A slow but steady growth trend in publications was observed, with a peak in 2018.
- The United States leads in publications (694), followed by Japan and China (382 each).
- Professor Michael Kreuter is identified as the most prolific author, with 19 publications.
- Five main co-cited literature clusters were identified, indicating distinct research themes.
- Keyword analysis predicts "nintedanib," "pirfenidone," and "immunotherapy" as future hot topics.
- The average number of citations per paper peaked in 2020, indicating a strong academic impact in that year.
- The study identified five main keyword clusters, with "Pulmonary fibrosis and lung cancer," "Pulmonary interstitial fibrosis," and "Lung cancer" being prominent.
Limitations and Future Work
Limitations:
- Database Scope: The analysis is limited to articles indexed in the Web of Science Core Collection (WoSCC), potentially excluding relevant research published in non-SCI journals or other databases.
- Systematic Retrieval: While advanced tools were used, bibliometric analysis cannot fully replace systematic retrieval and may not capture all nuances of the research landscape.
- Citation Bias: Citation counts are time-dependent, potentially favoring older publications. The study acknowledges this by using normalized citations in some analyses.
- Quality Assessment: Bibliometrics does not evaluate the quality of individual studies, only their publication and citation metrics.
Future Work:
- Drug Development: Future research will likely focus on drug experiments, exploring signaling pathways and growth factors to improve clinical survival and identify new therapeutic drugs with good efficacy and minimal harm.
- Combination Therapies: The study suggests that future treatment strategies may involve combinations of drugs targeting different aspects of both conditions.
- Biomarker Discovery: Continued exploration of reliable biomarkers for early detection and prognosis is a key area.
- Tumor Microenvironment: Further investigation into the connection between the tumor microenvironment and the comorbidity of pulmonary fibrosis and lung cancer is warranted.
- COVID-19 Impact: The paper highlights the emerging importance of understanding the relationship between COVID-19 and the comorbidity of pulmonary fibrosis and lung cancer, suggesting it as a future research hotspot.
Summary updated